ArticleThe Journal of infectious diseases2025
Comparative Analysis of Glucuronoxylomannogalactan and Glucuronoxylomannan Antibody Responses and Their Associations With Cryptococcal Disease Status in People With HIV.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundCryptococcosis remains a major cause of mortality in people with HIV (PWH). While glucuronoxylomannan-binding immunoglobulin G (GXM-IgG) levels have been associated with disease status and survival, the clinical significance of glucuronoxylomannogalactan-binding IgG (GXMGal-IgG) has not been investigated.
methodsWe analyzed serological data from 2 previously reported cohorts of PWH: a prospective asymptomatic South African cohort (67 cryptococcal antigen [CrAg] positive, 130 CrAg negative), and a Vietnamese case-control cohort (30 with symptomatic cryptococcal meningitis [CM], 30 without), both followed for mortality for 6 months. Serum/plasma GXMGal-IgG levels were quantified by enzyme-linked immunosorbent assay and compared to previously reported GXM-IgG levels. Logistic regression adjusted for age, sex, and CD4 count examined associations between antibody levels and CrAg positivity or CM status, while Cox proportional hazards models adjusted for CD4 count estimated associations with time to mortality.
resultsHigher GXMGal-IgG was associated with CrAg positivity (odds ratio, 1.64; 95% confidence interval [CI], 1.14-2.36), not CM status. Among individuals with asymptomatic cryptococcal antigenemia, higher GXMGal-IgG trended toward higher survival (hazards ratio, 0.67; 95% CI, .41-1.09), but this was not statistically significant and no significant survival benefit was observed for those with CM.
conclusionsGXMGal-IgG was associated with CrAg positivity and showed a modest trend toward survival for individuals with asymptomatic cryptococcal antigenemia but had limited predictive value for CM or mortality. These findings in antigenemia largely parallel previous observations for GXM-IgG, although associations observed were generally weaker. Further studies are needed to clarify the immune response to GXMGal and its potential diagnostic or prognostic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.